Boron nanoparticles inhibit turnour growth by boron neutron capture therapy in the murine B16-OVA model
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Boron nanoparticles inhibit turnour growth by boron neutron capture therapy in the murine B16-OVA model. / Petersen, Mikkel Steen; Petersen, Charlotte Christie; Agger, Ralf; Sutmutter, Marjolein; Jensen, Martin Roland; Sørensen, Palle G.; Mortensen, Michael Wrang; Hansen, Thomas; Bjørnholm, Thomas; Gundersen, Hans Jørgen; Huiskamp, Rene; Hokland, Marianne.
I: Anticancer Research, Bind 28, 2008, s. 571-576.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Boron nanoparticles inhibit turnour growth by boron neutron capture therapy in the murine B16-OVA model
AU - Petersen, Mikkel Steen
AU - Petersen, Charlotte Christie
AU - Agger, Ralf
AU - Sutmutter, Marjolein
AU - Jensen, Martin Roland
AU - Sørensen, Palle G.
AU - Mortensen, Michael Wrang
AU - Hansen, Thomas
AU - Bjørnholm, Thomas
AU - Gundersen, Hans Jørgen
AU - Huiskamp, Rene
AU - Hokland, Marianne
PY - 2008
Y1 - 2008
N2 - Background: Boron neutron capture therapy usually relies on soluble, rather than particulate, boron compounds. This study evaluated the use of a novel boron nanoparticle for boron neutron capture therapy. Materials and Methods: Two hundred and fifty thousand B16-OVA tumour cells, pre-incubated with boron nanoparticles for 12 hours, were injected subcutaneously into C57BL16J mice. The tumour sites were exposed to different doses of neutron radiation one, four, or eight days after tumour cell inoculation. Results: When the tumour site was irradiated with thermal neutrons one day after injection, tumour growth was delayed and the treated mice survived longer than untreated controls (median survival time 20 days (N=8) compared with 10 days (N=7) for untreated mice). Conclusion: Boron nanoparticles significantly delay the growth of an aggressive B16-OVA tumour in vivo by boron neutron capture therapy.
AB - Background: Boron neutron capture therapy usually relies on soluble, rather than particulate, boron compounds. This study evaluated the use of a novel boron nanoparticle for boron neutron capture therapy. Materials and Methods: Two hundred and fifty thousand B16-OVA tumour cells, pre-incubated with boron nanoparticles for 12 hours, were injected subcutaneously into C57BL16J mice. The tumour sites were exposed to different doses of neutron radiation one, four, or eight days after tumour cell inoculation. Results: When the tumour site was irradiated with thermal neutrons one day after injection, tumour growth was delayed and the treated mice survived longer than untreated controls (median survival time 20 days (N=8) compared with 10 days (N=7) for untreated mice). Conclusion: Boron nanoparticles significantly delay the growth of an aggressive B16-OVA tumour in vivo by boron neutron capture therapy.
KW - Faculty of Science
M3 - Journal article
VL - 28
SP - 571
EP - 576
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
ER -
ID: 5996759